Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and

Table 4 Optimal CMV-derived HLA class I restricted CTL epitopes

Protein	HLA Restriction	Sequence	Position	Reference
pp65	B35	IPSINVHHY	123–131	[56]
pp65	B35	DDVWTSGSDSDEELV	397–411	[57]
pp65	B35	VFPTKDVAL	187–195	[17]
pp65	B38	PTFTSQYRIQGKL	367–379	[17]
pp65	B7	TPRVTGGGAM	417–426	[57]
pp65	B7	RPHERNGFTVL	265–275	[17]
pp65	A1	YSEHPTFTSQY	363–373	[17]
pp65	A1101	SVLGPISGHVLK	13–24	[17]
pp65	A2402	FTSQYRIQGKL	369–379	[17]
pp65	A68	FVFPTKDVALP	186–196	[17]
pp65	A2	NLVPMVATV	495–503	[57]
pp65	A2	VLGPISGHV	14–22	[58]
pp65	A2	MLNIPSINV	120–128	[58]
pp65	B44	EFFWDANDIY	512–521	[57]
pp65	A2402	VYALPLKML	113–121	[59]
pp65	A2402/Cw0401	QYDPVAALF	341–349	[60, 61]
pp65	B5201	QMWQARLTV	155–163	[62]
pp65	A0207	RIFAELEGV	522–530	[61]
pp65	A1101	ATVQGQNLK	501–509	[61]
pp65	B1501	KMQVIGDQY	215–223	[61]
pp65	B4001	CEDVPSGKL	232–240	[61]
pp65	B40	HERNGFTVL	267–275	[61]
pp65	B4006	AELEGVWQPA	525–534	[61]
pp65	B4403	SEHPTFTSQY	364–373	[61]
pp65	B5101	DALPGPCI	545–552	[61]
pp65	Cw0102	RCPEMISVL	7–15	[61]
pp65	Cw0801	VVCAHELVC	198–206	[61]
pp65	Cw1202	VAFTSHEHF	294–302	[61]
pp65	A33	SVNVHNPTGR	91–100	[63]
pp150	A0301	TTVYPPSSTAK	945–955	[17]
pp150	A68	QTVTSTPVQGR	792–802	[17]
IE	B7	CRVLCCYVL	309–317	[64]
IE	A2	YILEETSVM	315–323	[65]
IE	B18	ELKRKMIYM	199–207	[65]
IE	B18	CVETMCNEY	279–287	[65]
IE	B18	DEEDAIVAY	379–387	[65]
IE	B18	SDEEEAIVAYTL	378–389	[56]
GB	A2	FIAGNSAYEYV	618–628	[66]

ISSN: 1479-5876